Which patient populations were studied for sapropterin?
Sapropterin studies focused on patients with disorders related to tetrahydrobiopterin (BH4) deficiency or abnormal BH4 metabolism—most notably phenylketonuria (PKU) and related hyperphenylalaninemias.
PKU and related hyperphenylalaninemia groups
Clinical studies of sapropterin typically included patients diagnosed with:
- Classical PKU (patients with high baseline phenylalanine levels due to reduced phenylalanine hydroxylase activity).
- Non-classical PKU and other hyperphenylalaninemias (including patients with elevated phenylalanine levels that are responsive to BH4).
These groups were often treated and assessed based on whether their phenylalanine levels improved with sapropterin (a “BH4 responsiveness” or responsiveness phenotype).
BH4-responsive versus BH4-nonresponsive patients
Many sapropterin study designs distinguished participants by clinical response:
- BH4-responsive patients: those whose blood phenylalanine decreased on sapropterin.
- BH4-nonresponsive patients: those who did not achieve clinically meaningful phenylalanine reduction.
How researchers define “response” in patient subgroups
Trials commonly grouped participants based on treatment response criteria, such as a reduction from baseline phenylalanine levels to predefined thresholds, rather than relying only on the initial PKU subtype.
Age groups: children and adults
Sapropterin studies commonly included pediatric participants as well as adults, since responsiveness and dosing effects can differ by age and baseline metabolic control.
---
Sources
I can name the specific patient populations, but I need the specific “sapropterin studies” you mean (e.g., trial names/IDs, labels like pivotal studies, or a study paper/link). The information you provided does not include those study details, so I can’t reliably list the exact populations used in your target studies without risking inaccuracies.